Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 2
2004 3
2005 2
2006 3
2007 2
2008 2
2009 2
2010 3
2011 2
2012 6
2013 7
2014 7
2015 8
2016 6
2017 5
2018 14
2019 8
2020 27
2021 49
2022 65
2023 46
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Wang DY, et al. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. JAMA Oncol. 2018. PMID: 30242316 Free PMC article.
Combination PD-1/CTLA-4 deaths were frequently from colitis (32 [37%]) and myocarditis (22 [25%]). Fatal toxic effects typically occurred early after therapy initiation for combination therapy, anti-PD-1, and ipilimumab monotherapy (median 14.5, 40, and 40 days, respective …
Combination PD-1/CTLA-4 deaths were frequently from colitis (32 [37%]) and myocarditis (22 [25%]). Fatal toxic effects typically occu …
Dengue and the heart.
Araiza-Garaygordobil D, García-Martínez CE, Burgos LM, Saldarriaga C, Liblik K, Mendoza I, Martinez-Selles M, Scatularo CE, Farina JM, Baranchuk A; Neglected Tropical Diseases and other Infectious Diseases affecting the Heart (the NET‐Heart) project. Araiza-Garaygordobil D, et al. Cardiovasc J Afr. 2021 Sep-Oct 23;32(5):276-283. doi: 10.5830/CVJA-2021-033. Epub 2021 Jul 20. Cardiovasc J Afr. 2021. PMID: 34292294 Free PMC article. Review.
CV complications of dengue include rhythm abnormalities, hypotension, myocarditis, pericarditis and deterioration in myocardial function. ...
CV complications of dengue include rhythm abnormalities, hypotension, myocarditis, pericarditis and deterioration in myocardial funct …
COVID-19 and myocarditis: a systematic review and overview of current challenges.
Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, Aimo A, Prasad S. Castiello T, et al. Heart Fail Rev. 2022 Jan;27(1):251-261. doi: 10.1007/s10741-021-10087-9. Epub 2021 Mar 24. Heart Fail Rev. 2022. PMID: 33761041 Free PMC article. Review.
Its pathogenesis is not fully elucidated, but the two main theories foresee a direct role of ACE2 receptor and a hyperimmune response, which may also lead to isolated presentation of COVID-19-mediated myocarditis. The frequency and prognostic impact of COVID-19-mediated …
Its pathogenesis is not fully elucidated, but the two main theories foresee a direct role of ACE2 receptor and a hyperimmune response, which …
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, Nimri N, Saleem M, Bandyopadhyay D, Krittanawong C, Fadelallah Eljack MM, Tahir MJ, Waqar F. Yasmin F, et al. Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807. Immun Inflamm Dis. 2023. PMID: 36988252 Free PMC article. Review.
This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarct …
This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose incl …
Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review.
Cheng CY, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. Cheng CY, et al. Autoimmun Rev. 2022 Apr;21(4):103037. doi: 10.1016/j.autrev.2022.103037. Epub 2022 Jan 5. Autoimmun Rev. 2022. PMID: 34995763 Review.
Many systemic immune-mediated diseases (SIDs) may involve the heart and present as myocarditis with different histopathological pictures, i.e. lymphocytic, eosinophilic, granulomatous, and clinical features, ranging from a completely asymptomatic patient to life-threatenin …
Many systemic immune-mediated diseases (SIDs) may involve the heart and present as myocarditis with different histopathological pictu …
COVID-19 vaccine induced myocarditis in young males: A systematic review.
Knudsen B, Prasad V. Knudsen B, et al. Eur J Clin Invest. 2023 Apr;53(4):e13947. doi: 10.1111/eci.13947. Epub 2023 Jan 3. Eur J Clin Invest. 2023. PMID: 36576362 Free PMC article. Review.
BACKGROUND: Myocarditis is a rare but significant adverse event associated with COVID-19 vaccination, especially for men under 40. If the risk of myocarditis is not stratified by pertinent risk factors, it may be diluted for high-risk and inflated for low-risk group …
BACKGROUND: Myocarditis is a rare but significant adverse event associated with COVID-19 vaccination, especially for men under 40. If …
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A, Sporis ND, Lazar AL, Buruiana A, Ganea AM, Malinescu TV, Berechet BM, Fodor A, Sitar-Taut AV, Vlad VC, Negrean V, Orasan OH. Cozma A, et al. Int J Mol Sci. 2022 Sep 19;23(18):10948. doi: 10.3390/ijms231810948. Int J Mol Sci. 2022. PMID: 36142866 Free PMC article. Review.
A variety of cardiac-adverse effects are associated with ICI-based treatment, including pericarditis, arrhythmias, cardiomyopathy, and acute coronary syndrome, with myocarditis being the most studied due to its often-unexpected onset and severity. Overall, Myocarditis …
A variety of cardiac-adverse effects are associated with ICI-based treatment, including pericarditis, arrhythmias, cardiomyopathy, and acute …
Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.
Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJM, Shekarriz-Foumani R, Kolahi AA, Singh K, Safiri S. Fazlollahi A, et al. Rev Med Virol. 2022 Jul;32(4):e2318. doi: 10.1002/rmv.2318. Epub 2021 Dec 17. Rev Med Virol. 2022. PMID: 34921468 Review.
Males with a median age of 21 years had the highest frequency of myocarditis. Almost three quarters (74.4%) of cases with myocarditis had received the BNT162b2 vaccine and 87.7% had received the second dose of the vaccine. ...Cardiac magnetic resonance imaging, whic …
Males with a median age of 21 years had the highest frequency of myocarditis. Almost three quarters (74.4%) of cases with myocardi …
Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.
Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Pasupathy S, et al. Circulation. 2015 Mar 10;131(10):861-70. doi: 10.1161/CIRCULATIONAHA.114.011201. Epub 2015 Jan 13. Circulation. 2015. PMID: 25587100 Review.
Qualitative assessment of 46 publications evaluating the underlying pathophysiology responsible for MINOCA revealed the presence of a typical myocardial infarct on cardiac magnetic resonance imaging in only 24% of patients, with myocarditis occurring in 33% and no signific …
Qualitative assessment of 46 publications evaluating the underlying pathophysiology responsible for MINOCA revealed the presence of a typica …
Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.
Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Watanabe A, et al. JAMA Pediatr. 2023 Apr 1;177(4):384-394. doi: 10.1001/jamapediatrics.2022.6243. JAMA Pediatr. 2023. PMID: 36689319 Free PMC article.
The incidence of AEs that prevented normal daily activities was 8.8% (95% CI, 5.4%-14.2%) and that of myocarditis was estimated to be 1.8 per million (95% CI, 0.000%-0.001%) following the second injection. ...
The incidence of AEs that prevented normal daily activities was 8.8% (95% CI, 5.4%-14.2%) and that of myocarditis was estimated to be …
243 results